PlusPedia wird derzeit technisch modernisiert. Aktuell laufen Wartungsarbeiten. Für etwaige Unannehmlichkeiten bitten wir um Entschuldigung; es sind aber alle Artikel zugänglich und Sie können PlusPedia genauso nutzen wie immer.

Neue User bitte dringend diese Hinweise lesen:

Anmeldung - E-Mail-Adresse Neue Benutzer benötigen ab sofort eine gültige Email-Adresse. Wenn keine Email ankommt, meldet Euch bitte unter NewU25@PlusPedia.de.

Hinweis zur Passwortsicherheit:
Bitte nutzen Sie Ihr PlusPedia-Passwort nur bei PlusPedia.
Wenn Sie Ihr PlusPedia-Passwort andernorts nutzen, ändern Sie es bitte DORT bis unsere Modernisierung abgeschlossen ist.
Überall wo es sensibel, sollte man generell immer unterschiedliche Passworte verwenden! Das gilt hier und im gesamten Internet.
Aus Gründen der Sicherheit (PlusPedia hatte bis 24.07.2025 kein SSL | https://)

Bei PlusPedia sind Sie sicher: – Wir verarbeiten keine personenbezogenen Daten, erlauben umfassend anonyme Mitarbeit und erfüllen die Datenschutz-Grundverordnung (DSGVO) vollumfänglich. Es haftet der Vorsitzende des Trägervereins.

PlusPedia blüht wieder auf als freundliches deutsches Lexikon.
Wir haben auf die neue Version 1.43.3 aktualisiert.
Wir haben SSL aktiviert.
Hier geht es zu den aktuellen Aktuelle Ereignissen

Lunge (Neubildung NSCLC)

Aus PlusPedia
Zur Navigation springen Zur Suche springen
Entstehender Artikel
Siehe auch
Freie Übersichtsartikel [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49][50][51][52][53][54][55][56][57][58][59][60][61][62][63][64][65][66][67][68][69][70][71][72][73][74][75][76][77][78][79][80][81][82][83][84][85][86][87][88][89][90][91][92][93][94][95][96][97][98][99][100][101][102][103][104][105][106][107][108][109][110][111][112][113][114][115][116][117][118][119][120][121][122][123][124][125][126][127][128][129][130][131][132][133][134][135][136][137][138][139][140][141][20][142][143][144][145][146][147][148][149][150][151][152][153][41][154][155][156][157][158][159][160][161][162][163][164][60][61][165][166][167][168][169][81][82][96][170][171][172][173][174]
Wichtige Übersichtsartikel
Medline Suchterm/ Synonyme
Was ist das
Struktur
Physiologie
Knockout
Transgen
Mutation
Polymorphismus
Genexpression
Inhibitoren
Agonisten

Bibliographie

  1. ↑ Adjuvant chemotherapy for completely resected non-small-cell lung cancer. Acta Med Okayama 63(5):223-30 (2009) PMID 19893597
  2. ↑ Gefitinib first or gefitinib second: is timing everything in the treatment of EGFR mutant non-small cell lung cancer? Am J Respir Crit Care Med 178(8):783-5 (2008) PMID 18832554
  3. ↑ Insulin-like growth factor-1 receptor-targeted therapy for non-small cell lung cancer: a mini review. Am J Transl Res 1(2):101-14 (2009) PMID 19956424
  4. ↑ Gefitinib for advanced non-small-cell lung cancer and quality of life: expanding and improving treatment options. Ann Oncol 20(9):1455-7 (2009) PMID 19704160
  5. ↑ Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20 Suppl 4():68-70 (2009) PMID 19454467
  6. ↑ Challenges treating older non-small cell lung cancer patients. Ann Oncol 19 Suppl 7():vii109-13 (2008) PMID 18790931
  7. ↑ Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19 Suppl 2():ii39-40 (2008) PMID 18456762
  8. ↑ The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg 15(1):4-9 (2009) PMID 19262443
  9. ↑ Current status and future direction of surgical treatment for non-small cell lung cancer. Ann Thorac Cardiovasc Surg 15(1):1-3 (2009) PMID 19262442
  10. ↑ Frontline gefitinib in advanced non-small cell lung cancer: Meta-analysis of published randomized trials. Ann Thorac Med 5(3):153-60 (2010) PMID 20835310
  11. ↑ Prognostic factors and long term results of neo adjuvant therapy followed by surgery in stage IIIA N2 non-small cell lung cancer patients. Ann Thorac Med 4(4):201-7 (2009) PMID 19881166
  12. ↑ Surface balance study of the interaction between microorganisms and lipid monolayer at the air/water interface. Appl Environ Microbiol 31(4):609-11 (1976) PMID 5058
  13. ↑ Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer. Biologics 4():237-43 (2010) PMID 20859451
  14. ↑ Management of patients with advanced non-small cell lung cancer: role of gefitinib. Biologics 4():83-90 (2010) PMID 20531966
  15. ↑ EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab. Biologics 3():215-24 (2009) PMID 19707410
  16. ↑ First- and second-line treatment of advanced metastatic non-small-cell lung cancer: a global view. BMC Proc 2 Suppl 2():S3 (2008) PMID 18831719
  17. ↑ The role of positron emission tomography in the management of non-small cell lung cancer. Can J Surg 52(3):235-42 (2009) PMID 19503669
  18. ↑ Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery. Cancer 115(18):4156-66 (2009) PMID 19551884
  19. ↑ Maintenance therapy in nonsmall-cell lung cancer: a new treatment paradigm. Cancer 115(22):5143-54 (2009) PMID 19658185
  20. ↑ 20,0 20,1 Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer: a Literature-based Meta-analysis. Cancer 115(9):1924-31 (2009) PMID 19235250
  21. ↑ Pneumonectomy after chemoradiation: the Dana-Farber Cancer Institute/Brigham and Women's Hospital experience. Cancer 112(5):1106-13 (2008) PMID 18286507
  22. ↑ Gefitinib in lung cancer therapy: clinical results, predictive markers of response and future perspectives. Cancer Biol Ther 8(3):206-12 (2009) PMID 19182534
  23. ↑ Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer. Cancer Chemother Pharmacol 65(6):1023-8 (2010) PMID 19680652
  24. ↑ Non-small cell lung cancer staging: proposed revisions to the TNM system. Cancer Imaging 8():181-5 (2008) PMID 18824424
  25. ↑ PET/CT for staging and monitoring non small cell lung cancer. Cancer Imaging 8 Spec No A():S27-31 (2008) PMID 18852078
  26. ↑ Radiofrequency ablation of pulmonary tumours: current status. Cancer Imaging 8():27-35 (2008) PMID 18331970
  27. ↑ Acute cholangitis due to pancreatic metastasis from squamous cell lung carcinoma: a case report and review of literature. Cases J 2():9113 (2009) PMID 20062690
  28. ↑ Histologic considerations for individualized systemic therapy approaches for the management of non-small cell lung cancer. Chest 136(4):1112-8 (2009) PMID 19809052
  29. ↑ Second-line treatments in non-small cell lung cancer. A systematic review of literature and metaanalysis of randomized clinical trials. Chest 135(6):1596-609 (2009) PMID 19225067
  30. ↑ The new lung cancer staging system. Chest 136(1):260-71 (2009) PMID 19584208
  31. ↑ Staging of lung cancer. Chest 133(3):593-5 (2008) PMID 18321899
  32. ↑ Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res 15(10):3600-9 (2009) PMID 19447868
  33. ↑ Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res 15(13):4493-8 (2009) PMID 19531624
  34. ↑ ***ENG*** Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. Clin Cancer Res 15(24):7502-7509 (2009) PMID 20008850
  35. ↑ Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer. Clin Cancer Res 15(16):5040-8 (2009) PMID 19671872
  36. ↑ Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res 14(21):7060-7 (2008) PMID 18981003
  37. ↑ Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 14(10):2895-9 (2008) PMID 18483355
  38. ↑ The role for surgery in stage III non-small-cell lung cancer: can we reliably select the right patients? Clin Lung Cancer 10(5):314-6 (2009) PMID 19808188
  39. ↑ Management and prognosis in synchronous solitary resected brain metastasis from non-small-cell lung cancer. Clin Lung Cancer 10(3):174-9 (2009) PMID 19443337
  40. ↑ Advanced non-small-cell lung cancer in the elderly. Clin Lung Cancer 10(3):158-67 (2009) PMID 19443335
  41. ↑ 41,0 41,1 Induction chemotherapy and chemoradiation therapy for inoperable locally advanced non-small-cell lung cancer: a single-institution review of two different regimens. Clin Lung Cancer 10(2):124-9 (2009) PMID 19362956
  42. ↑ Second-line therapy for non-small-cell lung cancer. Clin Lung Cancer 10(2):91-8 (2009) PMID 19362951
  43. ↑ Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 10(4):281-9 (2009) PMID 19632948
  44. ↑ Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer 10(1):28-35 (2009) PMID 19289369
  45. ↑ Beyond doublet chemotherapy for advanced non-small-cell lung cancer: combination of targeted agents with first-line chemotherapy. Clin Lung Cancer 10(1):20-7 (2009) PMID 19289368
  46. ↑ New treatment strategies in patients with advanced non-small-cell lung cancer and performance status 2. Clin Lung Cancer 9(6):326-30 (2008) PMID 19073514
  47. ↑ Monoclonal antibodies versus tyrosine kinase inhibitors concurrent with chemotherapy in non-small-cell lung cancer: exploring divergent results. Clin Lung Cancer 9(3):141-3 (2008) PMID 18621622
  48. ↑ Mortality related to neoadjuvant therapy and surgery for stage III non-small-cell lung cancer. Clin Lung Cancer 9(4):213-6 (2008) PMID 18650168
  49. ↑ Stereotactic radiation therapy for inoperable, early-stage non-small-cell lung cancer. CMAJ 180(13):1326-8 (2009) PMID 19546457
  50. ↑ Systemic therapies in metastatic non-small-cell lung cancer with emphasis on targeted therapies: the rational approach. Curr Oncol 17(2):13-23 (2010) PMID 20404973
  51. ↑ Optimizing the management of advanced non-small-cell lung cancer: a personal view. Curr Oncol 16(4):9-21 (2009) PMID 19672420
  52. ↑ Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib. Curr Oncol 15(6):279-85 (2008) PMID 19079629
  53. ↑ Stereotactic body radiation therapy (stereotactic ablative radiotherapy) for stage I non-small cell lung cancer--updates of radiobiology, techniques, and clinical outcomes. Discov Med 9(48):411-7 (2010) PMID 20515609
  54. ↑ Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer. Discov Med 9(49):538-45 (2010) PMID 20587343
  55. ↑ Lung cancer: current diagnosis and treatment. Dtsch Arztebl Int 106(49):809-18; quiz 819-20 (2009) PMID 20038979
  56. ↑ Adjuvant chemotherapy after complete resection of non-small cell lung cancer. Dtsch Arztebl Int 105(14):249-54 (2008) PMID 19629205
  57. ↑ Integrated PET/CT in the staging of nonsmall cell lung cancer: technical aspects and clinical integration. Eur Respir J 33(1):201-12 (2009) PMID 19118231
  58. ↑ First- and second-line therapy for advanced nonsmall cell lung cancer. Eur Respir J 33(4):915-30 (2009) PMID 19336594
  59. ↑ Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. Health Technol Assess 14(Suppl. 2):71-9 (2010) PMID 21047494
  60. ↑ 60,0 60,1 Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer. Health Technol Assess 14(Suppl. 2):33-9 (2010) PMID 21047489
  61. ↑ 61,0 61,1 Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. Health Technol Assess 14 Suppl 1():47-53 (2010) PMID 20507803
  62. ↑ Erlotinib for the treatment of relapsed non-small cell lung cancer. Health Technol Assess 13 Suppl 1():41-7 (2009) PMID 19567213
  63. ↑ Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer. Int J Med Sci 5(4):209-17 (2008) PMID 18645621
  64. ↑ In elderly patients with lung cancer is resection justified in terms of morbidity, mortality and residual quality of life? Interact Cardiovasc Thorac Surg 10(6):1015-21 (2010) PMID 20354037
  65. ↑ Does surgery for primary non-small cell lung cancer and cerebral metastasis have any impact on survival? Interact Cardiovasc Thorac Surg 8(4):467-73 (2009) PMID 19155223
  66. ↑ American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 27(36):6251-66 (2009) PMID 19917871
  67. ↑ Updates in non-small cell lung cancer--insights from the 2009 45th annual meeting of the American Society of Clinical Oncology. J Hematol Oncol 3():18 (2010) PMID 20433767
  68. ↑ Recent advances of novel targeted therapy in non-small cell lung cancer. J Hematol Oncol 2():2 (2009) PMID 19159467
  69. ↑ Role of 18F-FDG PET in assessment of response in non-small cell lung cancer. J Nucl Med 50 Suppl 1():31S-42S (2009) PMID 19380411
  70. ↑ American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Oncol Pract 6(1):39-43 (2010) PMID 20539732
  71. ↑ Cost effectiveness of evidence-based treatment guidelines for the treatment of non-small-cell lung cancer in the community setting. J Oncol Pract 6(1):12-8 (2010) PMID 20539725
  72. ↑ Factors associated with decisions to undergo surgery among patients with newly diagnosed early-stage lung cancer. JAMA 303(23):2368-76 (2010) PMID 20551407
  73. ↑ Overview of gefitinib in non-small cell lung cancer: an Asian perspective. Jpn J Clin Oncol 39(3):137-50 (2009) PMID 19088154
  74. ↑ Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 375(9722):1267-77 (2010) PMID 20338627
  75. ↑ Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83(5):584-94 (2008) PMID 18452692
  76. ↑ Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol 21 Suppl 2():S16-22 (2008) PMID 18437168
  77. ↑ Rational use of cetuximab in the treatment of advanced non-small cell lung cancer. Onco Targets Ther 2():251-60 (2009) PMID 20616912
  78. ↑ Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 28 Suppl 1():S24-31 (2009) PMID 19680293
  79. ↑ Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy. Oncologist 14(9):909-20 (2009) PMID 19726457
  80. ↑ The role of EGFR inhibition in the treatment of non-small cell lung cancer. Oncologist 14(11):1116-30 (2009) PMID 19892771
  81. ↑ 81,0 81,1 Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach. Oncologist 14(5):497-510 (2009) PMID 19423674
  82. ↑ 82,0 82,1 The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 14(3):253-63 (2009) PMID 19221167
  83. ↑ Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer. Oncologist 14(6):601-11 (2009) PMID 19482958
  84. ↑ Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer. Oncologist 14(6):612-20 (2009) PMID 19474164
  85. ↑ Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. Oncologist 14(4):399-411 (2009) PMID 19357226
  86. ↑ Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist 14(4):378-90 (2009) PMID 19349511
  87. ↑ The role of the taxanes in the treatment of older patients with advanced stage non-small cell lung cancer. Oncologist 14(4):412-24 (2009) PMID 19342473
  88. ↑ Consensus conference: multimodality management of early- and intermediate-stage non-small cell lung cancer. Oncologist 13(9):945-53 (2008) PMID 18779538
  89. ↑ Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC. Oncologist 13(11):1166-76 (2008) PMID 18997180
  90. ↑ Critical review of nonsurgical treatment options for stage I non-small cell lung cancer. Oncologist 13(3):309-19 (2008) PMID 18378542
  91. ↑ Modern radiotherapy as part of combined modality treatment in locally advanced non-small cell lung cancer: present status and future prospects. Oncologist 13(6):700-8 (2008) PMID 18586925
  92. ↑ Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion. Oncologist 13 Suppl 1():37-46 (2008) PMID 18263773
  93. ↑ Considerations for second-line therapy of non-small cell lung cancer. Oncologist 13 Suppl 1():28-36 (2008) PMID 18263772
  94. ↑ Local control of regional and metastatic lesions and indication for systemic chemotherapy in patients with non-small cell lung cancer. Oncologist 13 Suppl 1():21-7 (2008) PMID 18263771
  95. ↑ Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer. Oncologist 13 Suppl 1():14-20 (2008) PMID 18263770
  96. ↑ 96,0 96,1 Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist 13 Suppl 1():5-13 (2008) PMID 18263769
  97. ↑ ***ENG*** EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget 1(7):497-514 (2010) PMID 21165163
  98. ↑ EGFR-targeted therapies in lung cancer: predictors of response and toxicity. Pharmacogenomics 10(1):59-68 (2009) PMID 19102716
  99. ↑ Nodal metastasis in non-small cell lung cancer: accuracy of 3.0-T MR imaging. Radiology 246(2):596-604 (2008) PMID 18056854
  100. ↑ Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging. Radiology 248(2):632-42 (2008) PMID 18552311
  101. ↑ Non-small cell lung cancer: whole-body MR examination for M-stage assessment--utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT. Radiology 248(2):643-54 (2008) PMID 18539889
  102. ↑ Intensity-modulated radiation therapy (IMRT) for inoperable non-small cell lung cancer: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience. Radiother Oncol 87(1):17-23 (2008) PMID 18343515
  103. ↑ Non-small cell lung cancer in the elderly: defining treatment options. Semin Oncol 35(6):590-6 (2008) PMID 19027463
  104. ↑ CyberKnife stereotactic ablative radiotherapy for lung tumors. Technol Cancer Res Treat 9(6):589-96 (2010) PMID 21070081
  105. ↑ Lung adenocarcinoma presenting as obstructive jaundice: a case report and review of literature. World J Surg Oncol 6():120 (2008) PMID 19014447
  106. ↑ Phase II trial of gemcitabine and cisplatin sequentially administered in Asian patients with unresectable or metastatic non-small cell lung cancer. Ann Acad Med Singapore 35(1):33-7 (2006) PMID 16470272
  107. ↑ Outcomes of concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer and significant comorbidity. Ann Oncol 22(1):132-8 (2011) PMID 20595452
  108. ↑ Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 21(9):1804-9 (2010) PMID 20150572
  109. ↑ Gemcitabine and pemetrexed combination: the key role of the sequence of drugs administration. Ann Oncol 20(10):1747-8 (2009) PMID 19690055
  110. ↑ Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104). Ann Oncol 20(5):835-41 (2009) PMID 19164456
  111. ↑ Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial. Ann Oncol 20(5):850-6 (2009) PMID 19150937
  112. ↑ Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group. Ann Oncol 19(1):115-22 (2008) PMID 17938425
  113. ↑ Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03. Ann Oncol 19(4):739-45 (2008) PMID 18096565
  114. ↑ Phase III study in stage IV non-small-cell lung cancer patients treated with two courses of cisplatin/gemcitabine followed by a randomization to three additional courses of the same combination or gemcitabine alone. Ann Oncol 18(5):903-8 (2007) PMID 17351253
  115. ↑ The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann Oncol 18(3):453-60 (2007) PMID 17322539
  116. ↑ Randomized phase II trial of gemcitabine plus weekly versus three-weekly paclitaxel in previously untreated advanced non-small-cell lung cancer. Ann Oncol 18(1):110-5 (2007) PMID 17043094
  117. ↑ Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18(2):317-23 (2007) PMID 17079694
  118. ↑ Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101). Ann Oncol 18(2):324-30 (2007) PMID 17071935
  119. ↑ Review of the pemetrexed and gemcitabine combination in patients with advanced-stage non-small cell lung cancer. Ann Oncol 17 Suppl 5():v86-90 (2006) PMID 16807472
  120. ↑ Non-platinum combination of gemcitabine in NSCLC. Ann Oncol 17 Suppl 5():v82-5 (2006) PMID 16807471
  121. ↑ Non-small-cell lung cancer: which platinum for gemcitabine? Ann Oncol 17 Suppl 5():v79-81 (2006) PMID 16807470
  122. ↑ Chemotherapy of advanced NSCLC in special patient population. Ann Oncol 17 Suppl 5():v72-8 (2006) PMID 16807469
  123. ↑ First line chemotherapy in advanced or metastatic NSCLC. Ann Oncol 17 Suppl 5():v64-7 (2006) PMID 16807466
  124. ↑ Clinical studies of pemetrexed and gemcitabine combinations. Ann Oncol 17 Suppl 5():v29-32 (2006) PMID 16807459
  125. ↑ Chemotherapy of advanced non-small cell lung cancer in elderly patients. Ann Oncol 17 Suppl 2():ii58-60 (2006) PMID 16608986
  126. ↑ A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer. Ann Oncol 17(7):1128-33 (2006) PMID 16670205
  127. ↑ Gemcitabine and radiation therapy in non-small cell lung cancer: state of the art. Ann Oncol 17(12):1743-7 (2006) PMID 16766586
  128. ↑ Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer. Ann Oncol 14(2):242-7 (2003) PMID 12562651
  129. ↑ Gemcitabine-induced systemic capillary leak syndrome. Ann Oncol 12(11):1651-2 (2001) PMID 11822767
  130. ↑ Pemetrexed: a multitargeted antifolate agent with promising activity in solid tumors. Ann Oncol 11(10):1335-41 (2000) PMID 11106124
  131. ↑ Paclitaxel and carboplatin in combination with gemcitabine: a phase I-II trial in patients with advanced non-small-cell lung cancer. Gruppo Studio Tumori Polmonari Veneto (GSTPV). Ann Oncol 11(11):1421-6 (2000) PMID 11142482
  132. ↑ A phase II study of a novel gemcitabine plus cisplatin regimen administered every three weeks for advanced non-small-cell lung cancer. Ann Oncol 9(4):457-9 (1998) PMID 9636840
  133. ↑ In vitro study on the schedule-dependency of the interaction between pemetrexed, gemcitabine and irradiation in non-small cell lung cancer and head and neck cancer cells. BMC Cancer 10():441 (2010) PMID 20723210
  134. ↑ First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study. Br J Cancer 98(3):558-63 (2008) PMID 18212755
  135. ↑ Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer 97(3):283-9 (2007) PMID 17595658
  136. ↑ Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients. Br J Cancer 91(3):489-97 (2004) PMID 15266334
  137. ↑ Supportive care in patients with advanced non-small-cell lung cancer. Br J Cancer 89(6):1013-21 (2003) PMID 12966418
  138. ↑ Domiciliary chemotherapy with gemcitabine is safe and acceptable to advanced non-small-cell lung cancer patients: results of a feasibility study. Br J Cancer 89(12):2190-6 (2003) PMID 14676793
  139. ↑ Platinum drugs in the treatment of non-small-cell lung cancer. Br J Cancer 87(8):825-33 (2002) PMID 12373594
  140. ↑ Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer 83(4):447-53 (2000) PMID 10945489
  141. ↑ Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br J Cancer 80(7):981-90 (1999) PMID 10362105
  142. ↑ Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research Network. Cancer 110(9):2027-34 (2007) PMID 17823908
  143. ↑ Sequential chemotherapy in nonsmall-cell lung cancer: cisplatin and gemcitabine followed by docetaxel. Cancer 109(4):727-31 (2007) PMID 17238182
  144. ↑ Weekly paclitaxel and gemcitabine chemotherapy for metastatic non-small cell lung carcinoma (NSCLC): a dose-optimizing phase II trial. Cancer 97(9):2242-7 (2003) PMID 12712478
  145. ↑ Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer 98(3):542-53 (2003) PMID 12879472
  146. ↑ Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel. Cancer 92(1):146-52 (2001) PMID 11443620
  147. ↑ Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin. Oncopaz Cooperative Group. Cancer 86(8):1463-9 (1999) PMID 10526274
  148. ↑ Gemcitabine and carboplatin combination chemotherapy for elderly patients with advanced Non-Small Cell Lung Cancer: a feasibility study. Cancer Res Treat 40(3):116-20 (2008) PMID 19688117
  149. ↑ Significant progress in palliative treatment of non-small cell lung cancer in the past decade. Chest 127(3):738-47 (2005) PMID 15764752
  150. ↑ Chemotherapy for non-small cell lung cancer in elderly patients. Chest 128(1):132-9 (2005) PMID 16002926
  151. ↑ Chemotherapy for elderly patients with non-small cell lung cancer: a review of the evidence. Chest 128(2):947-57 (2005) PMID 16100191
  152. ↑ A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients. Clin Cancer Res 14(13):4213-8 (2008) PMID 18594002
  153. ↑ Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel. Clin Cancer Res 10(15):5022-6 (2004) PMID 15297403
  154. ↑ Cisplatin plus gemcitabine as adjuvant chemotherapy for radically resected non-small-cell lung cancer: a pilot study. Clin Lung Cancer 10(1):53-7 (2009) PMID 19289373
  155. ↑ Weekly paclitaxel in elderly patients (aged > or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study. Clin Lung Cancer 9(5):280-4 (2008) PMID 18824450
  156. ↑ An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics of the TORCH trial. Clin Lung Cancer 9(4):235-8 (2008) PMID 18650174
  157. ↑ Gemcitabine/carboplatin in advanced non-small-cell lung cancer: data from randomized phase III trials. Clin Lung Cancer 4(2):76-9 (2002) PMID 14653862
  158. ↑ The value of platinum compounds in non-small-cell lung cancer. Clin Lung Cancer 3(4):249-53 (2002) PMID 14662032
  159. ↑ Gemcitabine-based doublets for advanced non-small-cell lung cancer: beyond gemcitabine/cisplatin. Clin Lung Cancer 3 Suppl 1():S10-6 (2002) PMID 14720349
  160. ↑ Gemcitabine and carboplatin in advanced non small-cell lung cancer: a review. Clin Lung Cancer 2 Suppl 1():S11-4 (2000) PMID 14725730
  161. ↑ Second and third line treatment in advanced non-small cell lung cancer. Discov Med 8(43):204-9 (2009) PMID 20040271
  162. ↑ A novel SH-type carboxypeptidase in the inner membrane of rat-liver mitochondria. Eur J Biochem 96(1):9-15 (1979) PMID 110590
  163. ↑ Chemotherapy improves low performance status lung cancer patients. Eur Respir J 30(6):1186-92 (2007) PMID 17690124
  164. ↑ Cost-utility analysis of chemotherapy in symptomatic advanced nonsmall cell lung cancer. Eur Respir J 27(5):895-901 (2006) PMID 16481384
  165. ↑ Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95(5):362-72 (2003) PMID 12618501
  166. ↑ Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J Thorac Oncol 3(10):1112-8 (2008) PMID 18827606
  167. ↑ Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 68(1):110-8 (2005) PMID 15795320
  168. ↑ Gemcitabine for the treatment of advanced nonsmall cell lung cancer. Onco Targets Ther 2():209-17 (2009) PMID 20616908
  169. ↑ Approval summary: pemetrexed in the initial treatment of advanced/metastatic non-small cell lung cancer. Oncologist 14(9):930-5 (2009) PMID 19737998
  170. ↑ Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature. Oncologist 12(4):451-64 (2007) PMID 17470688
  171. ↑ Optimizing first-line treatment options for patients with advanced NSCLC. Oncologist 10 Suppl 3():1-10 (2005) PMID 16368866
  172. ↑ Gemcitabine: single-agent and combination therapy in non-small cell lung cancer. Oncologist 4(3):241-51 (1999) PMID 10394591
  173. ↑ Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin. Proc Natl Acad Sci U S A 103(16):6332-7 (2006) PMID 16601104
  174. ↑ Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC). Ther Clin Risk Manag 4(3):579-85 (2008) PMID 18827853

Andere Lexika

Abgerufen von „https://h.suprapedia.de/w/index.php?title=Lunge_(Neubildung_NSCLC)&oldid=130262“